drugset
drugset / Trial / NCT05057949

A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants

NCT05057949 ↗

Phase 1 Completed 32 enrolled Sunshine Lake Pharma Co., Ltd.
Non-randomizedSequentialOpen-labelPrevention

Summary

The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.

Timeline

Start
2021-11-24
Primary completion
2022-02-17
Completion
2023-09-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 200 mg Oral
Subject Larotinib Unknown 350 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.